Abstract. The cytotoxic effect of anticancer drugs has been shown to involve induction of apoptosis. This observation raises the possibility that factors affecting caspase activation might be important determinants of anticancer drug sensitivity. Ectopic expression of caspase-1 has been shown to trigger apoptosis. However, the role of caspase-1 in apoptosis is now considered as minor compared to other caspases. In patients, high levels of caspase-1 expression may be associated with spontaneous regression in neuroblastomas and with a good clinical response to chemotherapy in acute myeloid leukemia and osteosarcoma. In experimental therapeutics for cancer, caspase-1 has been related to some anticancer activity. These observations led us to examine the effect of over-expression on the response to chemotherapy and radiotherapy in vitro and in vivo. Caspase-1 expression mediated by an adenoviral vector was able to kill directly cells and to sensitize the remaining cells to cisplatin or $\gamma$-radiation in vitro. In HeLa cells stably transfected with caspase-1, sensitization to cisplatin was due to an amplification of the cisplatin-induced mitochondrial apoptotic pathway activation. Caspase-1 mediated sensitization to cisplatin and $\gamma$-radiation was also observed in vivo. Altogether, we conclude that caspase-1 can act as a radio- and chemo-sensitizer, in vitro and in vivo.

Introduction

Apoptosis can be initiated by a variety of stimuli, including growth factors, UV, $\gamma$-irradiation, or chemotherapeutic drugs. This phenomenon is co-ordinated by a family of cysteine proteases, the caspases. They mediate proteolysis of certain target proteins that ultimately result in cell death. There are two major intracellular caspase cascades: one activated predominately by death receptor ligands and the other triggered by various cellular stresses, including DNA damage and microtubule disruption (1).

The cytotoxic effect of anticancer drugs has been shown to involve induction of apoptosis (2). This observation raises the possibility that factors affecting caspase activation and activity might be important determinants of anticancer drug sensitivity (3). For example, it has been demonstrated that inhibition of caspases was associated with resistance to chemotherapy in vivo (4). In particular, apoptosis induced in tumour cells by cytarabine, doxorubicin, methatrexate (5), cisplatin (6), ionizing radiation (7) or taxotere (8) required the activation of caspase-1 and -3 for induction of cell death. Ectopic expression of caspase-1 has been shown to trigger apoptosis. However, the role of caspase-1 in apoptosis has been revisited and it is now considered minor compared to caspase-3, -6, -7, -8, -9 (1).

The potential of caspase-1 in experimental therapeutics for cancer has been demonstrated: ICE was delivered by recombinant retrovirus (9), adenovirus (10) or via a gene gun (11).

In clinical studies, it has been suggested that caspase-1 may be associated with spontaneous regression of neuroblastomas (12). In addition, the correlation between the level of caspase-1 expression and the response to chemotherapy appears to depend on the type of cancer studied. In acute myeloid leukemia (13), and osteosarcoma (14), high expression of caspase-1 is correlated with a good clinical response to chemotherapy while high levels of serum caspase-1 are associated with non-response to biochemotherapy in melanoma (15).

These apparently conflicting data, as well as the potential of caspase-1 as a therapeutic target, led us to examine the effect of caspase-1 over-expression on its own and in combination with chemotherapy and radiotherapy in a panel of cell lines.
Materials and methods

**Plasmids.** Caspase-1 cDNA was amplified by PCR with the following set of primers (forward primer: 5'-CGGGGTACCCATGATGCCCAGTTCTG-3' and reverse primer: 5'-CTAGTCTAGATGCCCACAGACATTC-3') using the ICE-pBluescript vector (kindly given by Dr Fueyo) as a template. The PCR product was cloned into pEF6/V5-His-TOPO vector (Invitrogen, UK) and sequenced. One clone with the cDNA inserted in the correct orientation was chosen. In transfection experiments, an empty pEF6/V5-His-TOPO vector was used as a control.

The caspase-1 cDNA was inserted into the EcoRV/KpnI sites of pShuttle (16) to generate pSh-ICE. Once linearised with Pmel, pSh-ICE was then recombined with pAdeasy1 as previously described to generate pAd-ICE. Correct recombinants were selected by restriction endonuclease digestion.

**Adenoviral vectors.** Ad-GFP, was obtained from Qbiogene (Cambridge, UK), and Ad-Mock was an E1-deleted Ad-5 Adenoviral vectors. Ad-GFP, was obtained from Qbiogene (Cambridge, UK), and Ad-Mock was an E1-deleted Ad-5 vector containing no transgene (17). The virus Ad-ICE was generated after transfection of pAd-ICE into 293 cells. It was produced, purified and titrated as previously described (18).

**Cell lines.** Cervical carcinoma cell line HeLa, pancreatic cell lines Panc-O2, HPAF and Panc-1 and the human prostate cancer cell lines DU-145, PC-3, BHP-1, LNCaP, were obtained from the Research Cell Service of Cancer Research-UK. Cells were grown on DMEM or RPMI-1640 medium containing 10% fetal bovine serum in presence of antibiotics.

HeLa cells (10⁶) per well, were transfected with 0.4 μg of DNA in 6-well plates using Effectene transfection reagent (Qiagen, UK), according to the manufacturer's protocols with minor modifications, in order to construct HeLa-Topo and HeLa-ICE cell lines. Blasticidin S HCl (Invitrogen) resistant clones, were selected at doses of 10 μg/ml.

**Caspase-1 enzymatic assay.** p45-proICE is found in normal HeLa cells but does not form the active protease (19). Caspase-1 enzymatic activity was assayed using the caspase-1/ICE Colorimetric Protease Assay kit (MBL, Japan) according to the manufacturer's instructions, based on the cleavage of the YVAD-pNA substrate in the presence or absence of the caspase-1 selective inhibitor YVAD-FMK.

**In vitro cytotoxicity assay.** Cell lines (2x10⁴ cells), were plated onto 24-well plates with 1 ml of DMEM with 10% serum, with the only exception of the radiation experiments where 10⁴ cells per well were seeded. Twenty-four hours later, cells were infected with 1-10 p.f.u. per cell, and the next day, different concentrations of cisplatin (Sigma-Aldrich, UK), paclitaxel (Taxol, Calbiochem, CA), or γ-radiation were administered. For experiments on HeLa-Topo or HeLa-ICE, the treatment started 24 h after seeding of the cells. Five or seven days (for irradiation experiments) after the treatment started, 100 μl of MTT was added (5 mg/ml) (Sigma-Aldrich). The cells were incubated for 2 h at 37°C, dissolved in DMSO and the optical density at 540 nm was measured.

**Flow cytometry.** HeLa-Topo or HeLa-ICE cells (10⁶) were plated onto 6-cm diameter dishes and treated with cisplatin (1 μg/ml). At different times, cells were washed with PBS, and harvested. Protocol was followed as previously described (17), and samples were passed through a filter cap immediately prior to analysis on a FACSCalibur™ (Beckton-Dickinson).

**Western blots.** HeLa-Topo or HeLa-ICE cells (10⁶) were plated onto 6-cm diameter tissue culture dishes. The next day, cells were treated with 0, 0.3 or and 1 μg/ml of cisplatin and collected after 18 h of treatment. Cells and supernatant were pelleted, and 100 μl of lysis buffer (150 mm NaCl, 50 mM Tris pH 7.5, 0.05% SDS, 1% Triton X-100) was added. The resulting homogenate was sonicated on ice.

**Protein extract (20 μg)** was separated on 10-15% SDS-polyacrylamide gels and transferred onto nitrocellulose filters by semidry blotting. The primary antibodies used were mouse monoclonals anti-PARP IgG (1:2000) (Santa Cruz) and anti-caspase 8 IgG (1:1000) (Alexis Biochemicals, UK), a rabbit polyclonal anti-caspase-9 (1:500) (Santa Cruz, UK), and mouse monoclonal anti-GFP 3E1 (1:4000) (Cancer Research-UK Monoclonal Antibody Services). Secondary antibodies were a rabbit anti-mouse (1:1500) or a goat anti-rabbit (1:1500) HRP conjugated from Sigma. Antibody binding was visualized using ECL (Amersham Pharmacia Biotech, UK).

**Real-time PCR.** HeLa Topo or HeLa-ICE cells (10⁶) were plated onto 6-cm diameter tissue culture dishes. The next day, cells were treated with 0, 0.3, 0.5 or 1 μg/ml cisplatin and collected after 18 h of treatment. DNA was resuspended in 100 μl RNAase-free water and RNA (2 μg) was reverse transcribed using TaqMan reverse transcription reagents kit (ABI), as previously described (20).

Forward and reverse primers for cIAP-1, cIAP-2, XIAP and PGK-1 (endogenous control) were designed using Primer express software and used at a concentration of 300 nm/
300 nm. The sequences of the primers used are: cIAP1, TGTTGTCAACTTCAGATACCACTGG/CATCATGACAGCATCTTCTGAAGA; cIAP2, GGACAGGAGTTCATCCGTCAGA/TGGATAATTGATGACTCTGCATTTTC; XIAP, GACAGTATGCAAGATGAGTCAAGTCA/GCAAAGCTTCTCCTCTTGCA; PGK-1, TGGAGAACCTCCGCTTTCAT/TGGCTCGGCTTTAACCTTGT.

In vivo studies. HeLa-Topo or HeLa-ICE cells (10^6) were injected subcutaneously into 6-week-old female Balb/c nude mice. Experiments were conducted after appropriate local ethical approval. Nude mice were obtained from Harlan Iberica (Barcelona, Spain) and were kept in a germ-free environment with irradiated food and acidified water ad libitum. When a tumour reached 0.2 cm^2, groups of mice received a single intraperitoneal injection of cisplatin (Bristol-Myers-Squibb) of 1, 4, 7 or 10 mg/kg of weight, or PBS injection for controls.

For radiotherapy experiments, treated mice received semicorporal irradiation in an AECL Cobalt unit, at a skin surface distance of 80 cm and a radiation coefficient of 136 cGy/min. They received daily doses of 600 cGy up to a total of 12 Gy. The upper body was covered and the fractioning of the irradiation was chosen to minimize the toxicity produced by the irradiation. Tumour size was determined by two perpendicular measurements every other day, until the tumour size reached the limit authorised by the local ethical approval.

Results

Expression of caspase-1 mediated by an adenoviral vector in cell lines of different origins. Immunohistochemical studies showed that the majority of primary prostate cancer cells lacked caspase-1 protein expression compared with normal prostatic tissue (21) but on the contrary, over-expression of caspase-1 is observed in most of pancreatic cancer cells compared with normal pancreatic tissue (22).

In order to assess whether the responses to caspase-1 were tumour type-specific, we infected a panel of prostatic (DU-145, PC-3, BHP-1 or LNCaP), pancreatic (Panc-O2, Panc-1, HPAF) and cervical (HeLa) carcinoma cell lines with an adenovirus encoding caspase-1. For each cell line, the dose of virus used was determined by Ad-GFP which ensured 100% cell transfection without non-specific viral toxicity (data not shown).

Adenoviral expression of caspase-1 sensitises cells to anti-cancer treatments in vitro. To test the radio or chemosensitization produced by ICE over-expression after adenoviral infection, various cell lines were incubated for 5 or 7 days with several doses of cisplatin or γ-radiation. Fig. 2 shows that the extent of the effect of γ-radiation or cisplatin depends on the cell line studied. However, all cells infected with Ad-ICE showed a marked sensitization to different treatments compared with non-infected cells or infected with mock adenovirus.

Generation of a cell line over-expressing caspase-1. To examine further the effect of radio and chemotherapy on cells not sensitive to caspase-1 action, a HeLa cell line over-expressing caspase-1 was generated. The presence of the caspase-1 cDNA in the genome of HeLa-ICE cells was detected by PCR on genomic DNA and was absent from the control line HeLa-Topo (data not shown). Caspase-1 activity was measured on HeLa-Topo and HeLa-ICE cells treated with 0.3 μg/ml of cisplatin (CDDP). The specific enzymatic activities were 0.06 absorbance units/mg...
of protein for HeLa-Topo and 0.21 absorbance units/mg of protein for HeLa-ICE.

To compare their growth potential, both cell lines were seeded on day 0 and the number of cells was evaluated at days 1, 5 and 8. Fig. 3A shows that HeLa-ICE cells in vitro grow significantly more slowly than the control HeLa-Topo. To determine whether this difference is due to delayed cell cycle or concomitant cell growth and death of the HeLa-ICE cells, flow cytometry analysis of both cell lines was performed (Fig. 3B). No significant difference in the sub-G1 population (an indicator of apoptosis) was observed in untreated HeLa-Topo and HeLa-ICE cells (Fig. 3B). By contrast, the number of cells in G2/M (M4) and S phase (M3) was significantly increased in HeLa-ICE cells (Fig. 3B). The difference in cell number observed in Fig. 3A is therefore likely to be the result of a caspase-1-mediated delayed cell cycle.

Caspase-1 over-expression sensitises HeLa cells to γ-radiation, in vitro. To assess the effect of caspase-1 over-expression on the cell death induced by γ-radiation, HeLa-ICE cells were subjected to various doses of irradiation. Fig. 4A shows that γ-radiation can kill HeLa-Topo cells, in a dose-dependent manner. This toxic effect was enhanced in HeLa-ICE cells. This sensitisation is particularly observed at a low radiation dose (2 Gy), sufficient to induce the death of around half of the HeLa-ICE population, while HeLa-Topo cells remained largely unaffected (Fig. 4A).

Caspase-1 over-expression sensitises HeLa cells to chemotherapeutic agents in vitro. The effect of caspase-1 over-expression on the cell death induced by Taxol was examined by incubating HeLa-ICE or HeLa-Topo cells with various concentrations of the drug for 5 days. Fig. 4B shows a dose-dependent decrease in cell survival of the treated cells, with a modest but significant increased sensitivity of HeLa-ICE to Taxol. By contrast, when these experiments were repeated with cisplatin (CDDP), a dose-dependent decrease in cell survival was observed with doses of cisplatin as low as 0.5 μg/ml, with the entire population of HeLa-ICE cells being killed with a dose of 3 μg/ml. This effect was accompanied by an increase in the sub-G1 population, 24 and 48 h after the start of the treatment with 1 μg/ml of cisplatin (Fig. 3B). These data suggest that the increased sensitisation to cisplatin mediated by caspase-1 involves enhancement of apoptosis.
Caspase-1 amplifies cisplatin-induced mitochondrial apoptotic pathway. In response to a pro-apoptotic stimulus involving cytochrome-C release from the mitochondria, the 47 kDa pro-caspase-9 is cleaved into its small (12 kDa) and large (35 kDa) sub-units. Independently, activation of receptors mediating cell death (TNF-R1, TNF-R2, death receptor 3 and 4 or Fas) induce the activation of caspase-8 which result in its proteolytic cleavage (1). Both apoptotic pathways will ultimately converge to the activation of effector caspases, such as caspase-3 that will cleave cellular proteins like the poly (ADP-ribose)-polymerase (PARP) that is cleaved into p85 and p25 proteins. Incubation of HeLa-Topo cells with 0.3 or 1 μg/ml of cisplatin led to a very modest cleavage of caspase-9 that did not result in a significant PARP-cleavage (Fig. 5A). By contrast, incubation of HeLa-ICE cells with cisplatin led to a dose-dependent activation of caspase-9 paralleled by a PARP-cleavage (Fig. 5A). Under similar treatment, caspase-8 remained unaffected in both cell lines, indicating that caspase-1 over-expression amplifies the cisplatin-induced mitochondrial apoptotic pathway, without affecting the ligand-induced apoptotic pathway. Interestingly, this effect on the apoptotic cascade was accompanied by an increase in the levels of transcripts of the inhibitors of apoptosis such as XIAP, cIAP1 and -2 (Fig. 5B).

Caspase-1 as a chemo- and radio-sensitiser in vivo. To determine whether the caspase-1-mediated sensitisation obtained in vitro (Fig. 4) could be observed in vivo, HeLa-Topo or HeLa-ICE cells were injected subcutaneously into 6-week-old female Balb/c nu/nu mice. Tumours were treated (A and B) with cisplatin (CDDP) at doses of 4 or 10 mg/kg weight or PBS for the controls, or (C) with γ-radiation on 2 consecutive days (two doses leading to a total of 12 Gy), when they reached approximately the size of 0.2 cm². For both groups, the size at the start of the treatment was HeLa-Topo 0.21 ± SD: 0.05 and HeLa-ICE 0.2 ± SD: 0.06, respectively. The tumour sizes were measured every other day. These values represent an average of at least 8 tumours. For each time point, the size of the tumour treated is divided by the size of the non-treated tumour and this result is multiplied by 100. This value is then subtracted to 100% to obtain the tumour growth inhibition presented.
experiment was stopped. Dose-dependent response was obtained when doses of 1 and 7 mg/kg weight were injected (data not shown).

Similarly, two sessions of radiotherapy when the tumours reached around 0.2 cm² on 2 consecutive days (to a total of 12 Gy) led to a reduction in the rate of tumour growth in HeLa-Topo-bearing animals (Fig. 6C). Greater tumour regression was observed when HeLa-ICE-bearing animals were subjected to the same treatment (Fig. 6C), with 3/8 tumours remaining undetectable when the experiment was stopped.

Discussion

In the present study, we report that over-expression of caspase-1 by adenovirus is capable of killing a proportion of the cells infected. In addition, we show that the surviving cells expressing caspase-1 have increased sensitivity to radiotherapy and chemotherapy in vitro. This sensitisation appeared to be quantitatively more important when DNA-damaging agents (as cisplatin and γ-radiation) were used as opposed to a drug affecting microtubules like Taxol. In the case of sensitisation to cisplatin, the effect of caspase-1 is accompanied by an increase in mRNA levels of anti-apoptotic molecules such as XIAP and cIAP1 and cIAP2. Finally caspase-1 can sensitise HeLa cells to cisplatin or γ-radiation in vivo.

These data are in agreement with some clinical results associating caspase-1 with a favourable response to chemotherapy: in acute myeloid leukemia, high expression of caspase-1 indicated a good clinical response to chemotherapy (13) or a favourable prognosis; high levels of caspase-1 have been correlated with spontaneous regression in neuroblastoma (12). Also, the serum concentration of caspase-1 in high-grade osteosarcoma patients has been shown to correlate with a good response to chemotherapy (14). Similarly, high levels of expression of caspase-1 observed in low-grade astroglial tumours were seen in apoptotic areas of the tumours and that was correlated with longer survival (23). An immunohistochemical study revealed that the majority of primary prostate cancer lacked caspase-1 immunoreactivity whereas the remaining showed reduced expression compared with normal prostate (21). This set of data suggests that caspase-1 expression is probably negatively selected during the establishment of a primary prostate tumour.

By contrast, increased caspase-1 expression has been associated with a poorer prognosis in other types of malignancy. In pancreatic cancer, over-expression of caspase-1 is observed in a majority of cells, whereas normal pancreatic tissue shows only occasional immunoreactivity (22), suggesting an additional function of caspase-1 besides apoptosis to promote pancreatic malignancy.

Several proteins have already been suggested as radio- and/or chemo-sensitisers to cancer cells, some of them are currently being used in gene therapy clinical trials. In this respect, adenovirus-mediated delivery of p53 tumour suppressor gene is the best-documented and multiple evidence suggest that alteration of p53 functions result in reduced responses to anticancer agents (24). Therefore, replacement therapy using p53, in combination with DNA-damaging agents is a strategy currently developed in a growing number of malignancies, for which local disease control remains sub-optimal. The adenoavirus type 5 E1A protein and some mutants generated from it were also shown to sensitisise carcinoma cells to radio- and chemo-therapy in a p53-independent manner in vitro and in vivo in murine and human tumour models (25).

Previous studies on some of the cell lines that we used in the present work, were employed to correlate the sensitivity or resistance of the different cell lines to anticancer treatments with genetic factors described in the literature (26). Some of these genetic pathways involved genes such as different members of the IAP family (cIAP1 and 2, XIAP), mutations in p53, pro- and anti-apoptotic members of the Bcl-2 family (Bax, Bcl-2 or Bcl-xl), the androgen dependency or not, or the intrinsic status of caspase-1. Neither the kind of tumour or any of the studied factors, including caspase-1 expression was correlated with the response showed by the cell lines to treatments.

Caspase-1 has already demonstrated some effect in experimental therapeutica for cancer. Retroviral- (4) and adenoviral-mediated delivery (10) of caspase-1 induced apoptosis that correlated in vivo with an anti-tumour effect. Combined with our observations, these data demonstrate the potential of caspase-1 for cancer gene therapy protocols where caspase-1 gene delivery could be used in combination with chemotherapy or radiotherapy.

In conclusion, we propose to use caspase-1 as a radio- and chemo-sensitiser in cancer gene therapy protocols, possibly combining the vectors with tumour/tissue selective promoters to avoid the effect in other tissues. The tumour target would be ideally accessible and treatable by either or both types of agents. In this context, primary prostate cancer appears to be a suitable candidate disease as in addition to prostate selective promoters, caspase-1 expression is lost (21). This local treatment of an accessible primary tumour site could be complemented by immunotherapy in which caspase-1 could also be a key player interfering with the development of distant metastatic disease.

Acknowledgements

We are grateful to Mónica López-Barahona, Carlos Parada, Javier Hernandez, and Karin Knight for their assistance. Research in the laboratory of Georges Vassaux is supported by Cancer Research-UK, Royal Society-CSIC and Pilar Martín-Duque by Programa Ramón y Cajal del Ministerio de Educación y Ciencia Español and Universidad Francisco de Vitoria.

References